메뉴 건너뛰기




Volumn 12, Issue 4, 2011, Pages 517-531

Pharmacotherapy for pediatric soft-tissue sarcomas

Author keywords

Chemotherapy; Children; Non rhabdomyosarcoma soft tissue sarcoma; Rhabdomyosarcoma; Soft tissue sarcoma

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CEFIXIME; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ERIBULIN; ETOPOSIDE; EVEROLIMUS; GEFITINIB; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; MELPHALAN; MONOCLONAL ANTIBODY; NAVELBINE; PAZOPANIB; R 1507; RAPAMYCIN; RIDAFOROLIMUS; TEMOZOLOMIDE; TEMSIROLIMUS; TOPOTECAN; TROFOSFAMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

EID: 79951646505     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.524926     Document Type: Review
Times cited : (18)

References (118)
  • 1
    • 33847281230 scopus 로고    scopus 로고
    • Rhabdomyosarcoma and the undifferentiate.d sarcomas
    • Pizzo PA Poplack DG editors 5th edition. Lippincott Williams & Wilkins, Philadelphia, PA;
    • Wexler LH, Meyer WH, Helman LJ. Rhabdomyosarcoma and the undifferentiated sarcomas. In: Pizzo PA, Poplack DG, editors, Principles and practice of pediatric oncology. 5th edition. Lippincott Williams & Wilkins, Philadelphia, PA; 2006. p. 971-1001
    • (2006) Principles and Practice of Pediatric Oncology , pp. 971-1001
    • Wexler, L.H.1    Meyer, W.H.2    Helman, L.J.3
  • 2
    • 33947509741 scopus 로고    scopus 로고
    • Nonrhabdomyosarcomatous soft tissue sarcomas
    • PA Poplack DC editors 5th edition Lippincott Williams & Wilkins, Philadelphia;
    • Okcu MF, Hicks J, Merchant TE, et al. Nonrhabdomyosarcomatous soft tissue sarcomas. In: Pizzo PA, Poplack DC, editors, Principles and practice of pediatric oncology. 5th edition. Lippincott Williams & Wilkins, Philadelphia; 2006. p. 1033-73
    • (2006) Principles and Practice of Pediatric Oncology , pp. 1033-1073
    • Okcu, M.F.1    Hicks, J.2    Merchant, T.E.3
  • 6
    • 17544367893 scopus 로고    scopus 로고
    • Current chemotherapeutic strategies for rhabdomyosarcoma
    • DOI 10.1586/14737140.5.2.283
    • Ferrari A, Casanova M. Current chemotherapeutic strategies for rhabdomyosarcoma. Expert Rev Anticancer Ther 2005;5:283-94 (Pubitemid 40553093)
    • (2005) Expert Review of Anticancer Therapy , vol.5 , Issue.2 , pp. 283-294
    • Ferrari, A.1    Casanova, M.2
  • 7
    • 17544363935 scopus 로고    scopus 로고
    • New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas
    • DOI 10.1586/14737140.5.2.307
    • Ferrari A, Casanova M. New concepts for the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Expert Rev Anticancer Ther 2005;5:307-18 (Pubitemid 40553095)
    • (2005) Expert Review of Anticancer Therapy , vol.5 , Issue.2 , pp. 307-318
    • Ferrari, A.1    Casanova, M.2
  • 8
    • 0032794460 scopus 로고    scopus 로고
    • Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: An analysis of 121 patients treated at St jude childrens research hospital
    • Spunt SL, Poquette CA, Hurt YS, et al. Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol 1999;17:3697-705
    • (1999) J. Clin. Oncol. , vol.17 , pp. 3697-705
    • Spunt, S.L.1    Poquette, C.A.2    Hurt, Y.S.3
  • 10
    • 13344286225 scopus 로고    scopus 로고
    • Treatment for childhood rhabdomyosarcoma: The cost of cure
    • DOI 10.1016/S1470-2045(05)01733-X, PII S147020450501733X
    • Stevens MC. Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol 2005;6:77-84 (Pubitemid 40197701)
    • (2005) Lancet Oncology , vol.6 , Issue.2 , pp. 77-84
    • Stevens, M.C.G.1
  • 12
    • 62449192357 scopus 로고    scopus 로고
    • Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: Results from international society of pediatric oncology studies MMT 89 and 95
    • Defachelles AS, Rey A, Oberlin O, et al. Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: results from International Society of Pediatric Oncology studies MMT 89 and 95. J Clin Oncol 2009;27:1310-5
    • (2009) J. Clin. Oncol. , vol.27 , pp. 1310-1315
    • Defachelles, A.S.1    Rey, A.2    Oberlin, O.3
  • 14
    • 0023889668 scopus 로고
    • Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma
    • Carli M, Pastore G, Perilongo G, et al. Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma. J Clin Oncol 1988;6:654-8
    • (1988) J. Clin. Oncol. , vol.6 , pp. 654-658
    • Carli, M.1    Pastore, G.2    Perilongo, G.3
  • 16
    • 4644335909 scopus 로고    scopus 로고
    • Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: A report from the soft tissue sarcoma committee of the children's oncology group
    • DOI 10.1158/1078-0432.CCR-04-0654
    • Spunt SL, Smith LM, Ruymann FB, et al. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Clin Cancer Res 2004;10:6072-9 (Pubitemid 39287511)
    • (2004) Clinical Cancer Research , vol.10 , pp. 6072-6079
    • Spunt, S.L.1    Smith, L.M.2    Ruymann, F.B.3    Qualman, S.J.4    Donaldson, S.S.5    Rodeberg, D.A.6    Anderson, J.R.7    Crist, W.M.8    Link, M.P.9
  • 17
    • 38749137720 scopus 로고    scopus 로고
    • Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: An up-front window study in newly diagnosed children with high-risk metastatic disease
    • Bergeron C, Thiesse P, Rey A, et al. Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease. Eur J Cancer 2008;44:427-31
    • (2008) Eur. J. Cancer , vol.44 , pp. 427-431
    • Bergeron, C.1    Thiesse, P.2    Rey, A.3
  • 19
    • 0028964049 scopus 로고
    • The third Intergroup Rhabdomyosarcoma Study
    • Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-30
    • (1995) J. Clin. Oncol. , vol.13 , pp. 610-630
    • Crist, W.1    Gehan, E.A.2    Ragab, A.H.3
  • 20
    • 0027534434 scopus 로고
    • The Intergroup Rhabdomyosarcoma Studies come of age
    • Womer RB. The Intergroup Rhabdomyosarcoma Studies come of age. Cancer 1993;71:1719-21 (Pubitemid 23067384)
    • (1993) Cancer , vol.71 , Issue.5 , pp. 1719-1721
    • Womer, R.B.1
  • 21
    • 36849009613 scopus 로고    scopus 로고
    • Comparison of results of a pilot study of alternating vincristine/ doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: A report from the children's oncology group
    • DOI 10.1002/pbc.21093
    • Arndt CA, Hawkins DS, Meyer WH, et al. Comparison of results of a pilot study of alternating vincristine/ doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;50:33-6 (Pubitemid 350234262)
    • (2008) Pediatric Blood and Cancer , vol.50 , Issue.1 , pp. 33-36
    • Arndt, C.A.S.1    Hawkins, D.S.2    Meyer, W.H.3    Sencer, S.F.4    Neglia, J.P.5    Anderson, J.R.6
  • 22
    • 20144388870 scopus 로고    scopus 로고
    • The IVADo regimen - A pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: A pilot study on behalf of the European pediatric soft tissue sarcoma study group
    • DOI 10.1002/cncr.20928
    • Bisogno G, Ferrari A, Bergeron C, et al. The IVADo regimen - a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study on behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer 2005;103:1719-24 (Pubitemid 40490034)
    • (2005) Cancer , vol.103 , Issue.8 , pp. 1719-1724
    • Bisogno, G.1    Ferrari, A.2    Bergeron, C.3    Scagnellato, A.4    Prete, A.5    Alaggio, R.6    Casanova, M.7    D'Angelo, P.8    Di Cataldo, A.9    Carli, M.10
  • 23
    • 33746821135 scopus 로고    scopus 로고
    • Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group
    • DOI 10.1200/JCO.2005.01.9497
    • Lager JJ, Lyden ER, Anderson JR, et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2006;24:3415-22 (Pubitemid 46638898)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.21 , pp. 3415-3422
    • Lager, J.J.1    Lyden, E.R.2    Anderson, J.R.3    Pappo, A.S.4    Meyer, W.H.5    Breitfeld, P.P.6
  • 26
    • 0035155499 scopus 로고    scopus 로고
    • Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An intergroup rhabdomyosarcoma study
    • Pappo AS, Lyden E, Breneman J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J Clin Oncol 2001;19:213-19 (Pubitemid 32063499)
    • (2001) Journal of Clinical Oncology , vol.19 , Issue.1 , pp. 213-219
    • Pappo, A.S.1    Lyden, E.2    Breneman, J.3    Wiener, E.4    Teot, L.5    Meza, J.6    Crist, W.7    Vietti, T.8
  • 28
    • 70449698239 scopus 로고    scopus 로고
    • Vincristine actinomycin and cyclophosphamide compared with vincristine actinomycin and cyclophosphamide alternating with vincristine topotecan and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Childrens oncology group study d9803
    • Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803. J Clin Oncol 2009;27:5182-8
    • (2009) J. Clin. Oncol. , vol.27 , pp. 5182-5188
    • Arndt, C.A.1    Stoner, J.A.2    Hawkins, D.S.3
  • 30
    • 33846951814 scopus 로고    scopus 로고
    • Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The children's oncology group
    • DOI 10.1200/JCO.2006.07.1720
    • Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol 2007;25:362-9 (Pubitemid 350002984)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.4 , pp. 362-369
    • Pappo, A.S.1    Lyden, E.2    Breitfeld, P.3    Donaldson, S.S.4    Wiener, E.5    Parham, D.6    Crews, K.R.7    Houghton, P.8    Meyer, W.H.9
  • 31
    • 62449214642 scopus 로고    scopus 로고
    • Randomized phase II window study of two schedules of irinotecan CPT-11 and vincristine VCR in rhabdomyosarcoma RMS at first relapse/disease progression
    • abstract 10013
    • Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window study of two schedules of irinotecan (CPT-11) and vincristine (VCR) in rhabdomyosarcoma (RMS) at first relapse/disease progression. J Clin Oncol 2008;26(15 Suppl):abstract 10013
    • (2008) J. Clin. Oncol. , vol.26 , Issue.15
    • Mascarenhas, L.1    Lyden, E.R.2    Breitfeld, P.P.3
  • 33
    • 66849095621 scopus 로고    scopus 로고
    • UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan
    • Ferraldeschi R, Minchell LJ, Roberts SA, et al. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics 2009;10:733-9
    • (2009) Pharmacogenomics , vol.10 , pp. 733-739
    • Ferraldeschi, R.1    Minchell, L.J.2    Roberts, S.A.3
  • 34
    • 76749168084 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors
    • Furman WL, Navid F, Daw NC, et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 2009;27:4599-604
    • (2009) J. Clin. Oncol. , vol.27 , pp. 4599-4604
    • Furman, W.L.1    Navid, F.2    Daw, N.C.3
  • 36
    • 0033761232 scopus 로고    scopus 로고
    • Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and misnatch repair phenotypes in xenograft models
    • Houghton PJ, Stewart CF, Cheshire PJ, et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and misnatch repair phenotypes in xenograft models. Clin Cancer Res 2000;6:4110-18
    • (2000) Clin. Cancer Res. , vol.6 , pp. 4110-4118
    • Houghton, P.J.1    Stewart, C.F.2    Cheshire, P.J.3
  • 37
    • 0035008973 scopus 로고    scopus 로고
    • Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V
    • DOI 10.1097/00043426-200105000-00008
    • Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001;23:215-20 (Pubitemid 32524925)
    • (2001) Journal of Pediatric Hematology/Oncology , vol.23 , Issue.4 , pp. 215-220
    • Raney, R.B.1    Anderson, J.R.2    Barr, F.G.3    Donaldson, S.S.4    Pappo, A.S.5    Qualman, S.J.6    Wiener, E.S.7    Maurer, H.M.8    Crist, W.M.9
  • 38
    • 44249090013 scopus 로고    scopus 로고
    • Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from united states and european cooperative groups
    • Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008;26:2384-9
    • (2008) J. Clin. Oncol. , vol.26 , pp. 2384-2389
    • Oberlin, O.1    Rey, A.2    Lyden, E.3
  • 39
    • 0031051491 scopus 로고    scopus 로고
    • Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue
    • Report of the German/Austrian Pediatric Bone Marrow Transplantation Group.
    • Koscielniak E, Klingebiel TH, Peters C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997;19:227-31
    • (1997) Bone Marrow Transplant , vol.19 , pp. 227-231
    • Koscielniak, E.1    Klingebiel, T.H.2    Peters, C.3
  • 41
    • 0034918470 scopus 로고    scopus 로고
    • Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma
    • DOI 10.1097/00043426-200106000-00007
    • Weigel BJ, Breitfeld PP, Hawkins D, et al. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 2001;23:272-6 (Pubitemid 32662033)
    • (2001) Journal of Pediatric Hematology/Oncology , vol.23 , Issue.5 , pp. 272-276
    • Weigel, B.J.1    Breitfeld, P.P.2    Hawkins, D.3    Crist, W.M.4    Baker, K.S.5
  • 42
    • 70350602712 scopus 로고    scopus 로고
    • Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma
    • Bisogno G, Ferrari A, Prete A, et al. Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. Eur J Cancer 2009;45:3035-41
    • (2009) Eur. J. Cancer , vol.45 , pp. 3035-3041
    • Bisogno, G.1    Ferrari, A.2    Prete, A.3
  • 44
    • 0033977253 scopus 로고    scopus 로고
    • Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children
    • PII S0959804999002361
    • Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000;36:87-94 (Pubitemid 30035349)
    • (2000) European Journal of Cancer , vol.36 , Issue.1 , pp. 87-94
    • Womer, R.B.1    Daller, R.T.2    Fenton, J.G.3    Miser, J.S.4
  • 45
    • 79960454992 scopus 로고    scopus 로고
    • Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma RMS
    • Early results from Childrens Oncology Group (COG) ARST0431: abstract 9503
    • Weigel B, Lyden E, Anderson JR, et al.; Early results from Children's Oncology Group (COG) ARST0431. Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). J Clin Oncol 2010;28(15 Suppl):abstract 9503
    • (2010) J. Clin. Oncol. , vol.28 , Issue.15
    • Weigel, B.1    Lyden, E.2    Anderson, J.R.3
  • 49
    • 77953019735 scopus 로고    scopus 로고
    • Targets for cancer therapy in childhood sarcomas
    • 10.1016/j.ctrv.2010.02.007
    • Wachtel M, Schafer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 2010, doi:10.1016/j.ctrv.2010.02.007
    • (2010) Cancer Treat. Rev.
    • Wachtel, M.1    Schafer, B.W.2
  • 50
    • 77953026387 scopus 로고    scopus 로고
    • The role of the innovative therapies for children with cancer ITCC European consortium
    • 10.1016/j.ctrv.2010.02.008
    • Zwaan CM, Kearns P, Caron H, et al. The role of the 'innovative therapies for children with cancer' (ITCC) European consortium. Cancer Treat Rev 2010, doi:10.1016/j.ctrv.2010.02.008
    • (2010) Cancer Treat. Rev.
    • Zwaan, C.M.1    Kearns, P.2    Caron, H.3
  • 52
    • 0035728324 scopus 로고    scopus 로고
    • Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein
    • DOI 10.1054/ghir.2001.0244
    • Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001;11:289-97 (Pubitemid 34257726)
    • (2001) Growth Hormone and IGF Research , vol.11 , Issue.5 , pp. 289-297
    • Ayalon, D.1    Glaser, T.2    Werner, H.3
  • 54
    • 0028053410 scopus 로고
    • In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2
    • Kalebic T, Tsokos M, Helman LJ. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 1994;54:5531-4
    • (1994) Cancer Res.. , vol.54 , pp. 5531-5534
    • Kalebic, T.1    Tsokos, M.2    Helman, L.J.3
  • 55
    • 0032513524 scopus 로고    scopus 로고
    • Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R
    • DOI 10.100 2/(SICI)109 7-0215(199804 13)76:2<223:: AID-IJC9>3.0.CO;2-Z
    • Kalebic T, Blaskesley V, Slade C, et al. Expression of a kinase-deficient IGF-1-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing wild type IGF-1-R. Int J Cancer 1998;76:223-7 (Pubitemid 28180376)
    • (1998) International Journal of Cancer , vol.76 , Issue.2 , pp. 223-227
    • Kalebic, T.1    Blakesley, V.2    Slade, C.3    Plasschaert, S.4    Leroith, D.5    Lee Helman, J.6
  • 58
    • 54249157471 scopus 로고    scopus 로고
    • Addiction to elevated insulin-like growth factor 1 receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody
    • Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor 1 receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008;68:8039-48
    • (2008) Cancer Res.. , vol.68 , pp. 8039-8048
    • Cao, L.1    Yu, Y.2    Darko, I.3
  • 59
    • 33646404053 scopus 로고    scopus 로고
    • Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma
    • Taulli R, Scuoppo C, Bersani F, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006;66:4742-9
    • (2006) Cancer Res. , vol.66 , pp. 4742-4749
    • Taulli, R.1    Scuoppo, C.2    Bersani, F.3
  • 61
    • 55249083566 scopus 로고    scopus 로고
    • PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma
    • Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008;27:6550-60
    • (2008) Oncogene , vol.27 , pp. 6550-6560
    • Taniguchi, E.1    Nishijo, K.2    McCleish, A.T.3
  • 62
    • 0036196163 scopus 로고    scopus 로고
    • Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma
    • DOI 10.1006/geno.2002.6703
    • Barber T, Barber M, Tomescu O, et al. Identification of target genes regulated by PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. Genomics 2002;79:278-84 (Pubitemid 34211935)
    • (2002) Genomics , vol.79 , Issue.3 , pp. 278-284
    • Barber, T.D.1    Barber, M.C.2    Tomescu, O.3    Barr, F.G.4    Ruben, S.5    Friedman, T.B.6
  • 63
    • 33644817251 scopus 로고    scopus 로고
    • The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts
    • Wang W, Slevin M, Kumar S, Kumar P. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts. Int J Oncol 2005;27:1087-96
    • (2005) Int. J. Oncol. , vol.27 , pp. 1087-1096
    • Wang, W.1    Slevin, M.2    Kumar, S.3    Kumar, P.4
  • 64
    • 24344448690 scopus 로고    scopus 로고
    • Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines
    • Onisto M, Slongo M, Gregnanin L, et al. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 2005;27:791-98
    • (2005) Int. J. Oncol. , vol.27 , pp. 791-798
    • Onisto, M.1    Slongo, M.2    Gregnanin, L.3
  • 65
    • 28544444282 scopus 로고    scopus 로고
    • Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid
    • DOI 10.1038/sj.onc.1208939
    • Gee MF, Tsuchida R, Eichler-Jonsson C, et al. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005;24:8025-37 (Pubitemid 41746746)
    • (2005) Oncogene , vol.24 , Issue.54 , pp. 8025-8037
    • Gee, M.F.W.1    Tsuchida, R.2    Eichler-Jonsson, C.3    Das, B.4    Baruchel, S.5    Malkin, D.6
  • 66
    • 84875833298 scopus 로고    scopus 로고
    • A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma RMS and non-rhabdomyosarcoma soft tissue sarcoma NRSTS
    • abstract TPS330
    • Chisholm JC, Casanova M, Geoerger B, et al. A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). J Clin Oncol 2010;28(15 Suppl):abstract TPS330
    • (2010) J. Clin. Oncol. , vol.28 , Issue.15
    • Chisholm, J.C.1    Casanova, M.2    Geoerger, B.3
  • 68
    • 34548427415 scopus 로고    scopus 로고
    • The biology behind mTOR inhibition in sarcoma
    • DOI 10.1634/theoncologist.12-8-1007
    • Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma.Oncologist 2007;12:1007-18 (Pubitemid 47359144)
    • (2007) Oncologist , vol.12 , Issue.8 , pp. 1007-1018
    • Wan, X.1    Helman, L.J.2
  • 70
    • 70350227313 scopus 로고    scopus 로고
    • The Insulin-like growth factor-1 receptor-targeting antibody CP-751 871 suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma
    • Kurmasheva R, Dudkin L, Billuos C, et al. The Insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71
    • (2009) Cancer Res , vol.69 , pp. 7662-7671
    • Kurmasheva, R.1    Dudkin, L.2    Billuos, C.3
  • 71
    • 47249152832 scopus 로고    scopus 로고
    • Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas
    • Ferrari A. Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas. Expert Rev Anticancer Ther 2008;8:929-38
    • (2008) Expert Rev. Anticancer Ther. , vol.8 , pp. 929-938
    • Ferrari, A.1
  • 72
    • 33644667931 scopus 로고    scopus 로고
    • Malignant peripheral nerve sheath tumors in pediatric age: A report from the italian and german soft tissue sarcoma cooperative group
    • Carli M, Ferrari A, Mattke A, et al. Malignant peripheral nerve sheath tumors in pediatric age: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group. J Clin Oncol 2005;23:8422-30
    • (2005) J. Clin. Oncol. , vol.23 , pp. 8422-8430
    • Carli, M.1    Ferrari, A.2    Mattke, A.3
  • 74
    • 74949095728 scopus 로고    scopus 로고
    • Infantile fibrosarcoma: Place of chemotherapy and treatment proposals based on the European experience
    • Orbach D, Rey A, Cecchetto G, et al. Infantile fibrosarcoma: place of chemotherapy and treatment proposals based on the European experience. J Clin Oncol 2010;28:318-23
    • (2010) J. Clin. Oncol. , vol.28 , pp. 318-323
    • Orbach, D.1    Rey, A.2    Cecchetto, G.3
  • 78
    • 68149158316 scopus 로고    scopus 로고
    • Comparing children and adults with synovial sarcoma in the surveillance epidemiology and end results program 1983 to 2005: An analysis of 1268 patients
    • Sultan I, Rodriguez-Galindo IC, Saab R, et al. Comparing children and adults with synovial sarcoma in the surveillance, epidemiology and end results program, 1983 to 2005: an analysis of 1268 patients. Cancer 2009;115:3537-47
    • (2009) Cancer , vol.115 , pp. 3537-3547
    • Sultan, I.1    Rodriguez-Galindo, I.C.2    Saab, R.3
  • 79
    • 44449110447 scopus 로고    scopus 로고
    • Synovial sarcoma of children and adolescents: The prognostic role of axial sites
    • Ferrari A, Bisogno G, Alaggio R, et al. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer 2008;44:1202-9
    • (2008) Eur. J. Cancer , vol.44 , pp. 1202-1209
    • Ferrari, A.1    Bisogno, G.2    Alaggio, R.3
  • 84
    • 77953243719 scopus 로고    scopus 로고
    • Synovial sarcoma in childhood and adolescence: A retrospective series of 77 patients registered by the childrens cancer and leukaemia group between 1991 and 2006
    • published online 8 Mar 2010.1002/pbc.22453
    • Brennan B, Stevens M, Kelsey A, Stiller CA. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer 2010: published online 8 Mar 2010, doi 10.1002/pbc.22453
    • (2010) Pediatr Blood Cancer
    • Brennan, B.1    Stevens, M.2    Kelsey, A.3    Stiller, C.A.4
  • 89
    • 0028334634 scopus 로고
    • Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - Reduced local recurrence but no improvement in survival: A study on the European organization for research and treatment of cancer soft tissue sarcoma and bone sarcoma group
    • Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study on the European Organization for Research and Treatment of Cancer Soft Tissue Sarcoma and Bone Sarcoma Group. J Clin Oncol 1994;12:1137-49
    • (1994) J. Clin. Oncol. , vol.12 , pp. 1137-1149
    • Bramwell, V.1    Rouesse, J.2    Steward, W.3
  • 90
    • 0029005580 scopus 로고
    • Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group
    • Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45
    • (1995) J. Clin. Oncol. , vol.13 , pp. 1537-1545
    • Santoro, A.1    Tursz, T.2    Mouridsen, H.3
  • 91
    • 71949083033 scopus 로고    scopus 로고
    • Harmonizing adult and pediatric approaches to the treatment of soft tissue sarcoma
    • Ferrari A. Harmonizing adult and pediatric approaches to the treatment of soft tissue sarcoma. Expert Rev Anticancer Ther 2009;9:1541-3
    • (2009) Expert Rev. Anticancer Ther. , vol.9 , pp. 1541-1543
    • Ferrari, A.1
  • 93
    • 34548413977 scopus 로고    scopus 로고
    • Combined modalities approach for localized adult extremity soft-tissue sarcoma
    • DOI 10.1586/14737140.7.8.1135
    • Gronchi A, Olmi P, Casali PG. Combined modalities approach for localised adult extremity soft-tissue sarcoma. Expert Rev Anticancer Ther 2007;7:1135-44 (Pubitemid 47365006)
    • (2007) Expert Review of Anticancer Therapy , vol.7 , Issue.8 , pp. 1135-1144
    • Gronchi, A.1    Olmi, P.2    Casali, P.G.3
  • 94
    • 0035281643 scopus 로고    scopus 로고
    • Adjuvant chemotherapy for adult soft tissue sarcoma: Is there a standard of care?
    • Bramwell VHC. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol 2001;19:1235-7 (Pubitemid 32202525)
    • (2001) Journal of Clinical Oncology , vol.19 , Issue.5 , pp. 1235-1237
    • Bramwell, V.H.C.1
  • 95
    • 0031566814 scopus 로고    scopus 로고
    • Sarcoma meta-analysis collaboration adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: Meta-analysis of individual data
    • Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:1647-54
    • (1997) Lancet , vol.350 , pp. 1647-1654
  • 98
    • 23044441741 scopus 로고    scopus 로고
    • Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: A pediatric oncology group study
    • DOI 10.1200/JCO.2005.03.209
    • Pappo AS, Devidas M, Jenkins J, et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 2005;23:4031-8 (Pubitemid 46211307)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.18 , pp. 4031-4038
    • Pappo, A.S.1    Devidas, M.2    Jenkins, J.3    Rao, B.4    Marcus, R.5    Thomas, P.6    Gebhardt, M.7    Pratt, C.8    Grier, H.E.9
  • 100
    • 0028856442 scopus 로고
    • The present state of the art in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view
    • Verweij J, Mouridsen HT, Nielssen OS, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol 1995;20:193-201
    • (1995) Crit. Rev. Oncol. Hematol. , vol.20 , pp. 193-201
    • Verweij, J.1    Mouridsen, H.T.2    Nielssen, O.S.3
  • 103
    • 0033571557 scopus 로고    scopus 로고
    • Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face
    • Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034-7
    • (1999) Cancer , vol.86 , pp. 2034-2037
    • Fata, F.1    O'Reilly, E.2    Ilson, D.3
  • 104
    • 55949086834 scopus 로고    scopus 로고
    • Phase II trial of weekly paclitaxel for unresectable angiosarcoma: The ANGIOTAX study
    • Penel N, Bui B, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008;26:5269-74
    • (2008) J. Clin. Oncol. , vol.26 , pp. 5269-5274
    • Penel, N.1    Bui, B.2    Bay, J.O.3
  • 108
    • 38749093970 scopus 로고    scopus 로고
    • Trabectedin in metastatic ewings family tumors patients progressing after standard chemotherapy
    • abstract 1004
    • Dileo P, Grosso F, Casanova M, et al. Trabectedin in metastatic Ewing's family tumors patients progressing after standard chemotherapy. J Clin Oncol 2007;25(18S):abstract 10040
    • (2007) J. Clin. Oncol. , vol.25
    • Dileo, P.1    Grosso, F.2    Casanova, M.3
  • 109
    • 69449106265 scopus 로고    scopus 로고
    • Trabectedin in myxoid liposarcomas MLS: A long-term analysis of a single-institution series
    • Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009;20:1439-44
    • (2009) Ann. Oncol. , vol.20 , pp. 1439-1444
    • Grosso, F.1    Sanfilippo, R.2    Virdis, E.3
  • 113
    • 67650337802 scopus 로고    scopus 로고
    • Pazopanib a multikinase angiogenesis inhibitor in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organization for research and treatment of cancer - Soft tissue and bone sarcoma group eortc study 62043
    • SleiJfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 2009;27:3126-32
    • (2009) J. Clin. Oncol. , vol.27 , pp. 3126-3132
    • SleiJfer, S.1    Ray-Coquard, I.2    Papai, Z.3
  • 114
    • 37149033966 scopus 로고    scopus 로고
    • Survival results with AP23573, a novel mTOR inhibitor in patients with advanced soft tissue sarcomas: Update of a phase II trial
    • abstract 1007
    • Chawla SP, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue sarcomas: update of a phase II trial. J Clin Oncol 2007;25(18S):abstract 10076
    • (2007) J. Clin. Oncol. , vol.25
    • Chawla, S.P.1    Tolcher, A.W.2    Staddon, A.P.3
  • 115
    • 51449089221 scopus 로고    scopus 로고
    • Deferolimus trial 106 - A phase I trial evaluating 7 regimens of oral deforolimus AP23573 MK-8669
    • abstract 3509
    • Mita MM, Britten CD, Poplin E, et al. Deferolimus trial 106 - a phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669). J Clin Oncol 2008;26(15S):abstract 3509
    • (2008) J. Clin. Oncol. , vol.26
    • Mita, M.M.1    Britten, C.D.2    Poplin, E.3
  • 116
    • 79951628241 scopus 로고    scopus 로고
    • Updating progress in sarcoma therapy with mTOR inhibitors
    • Epub ahead of print]
    • Blay JY. Updating progress in sarcoma therapy with mTOR inhibitors. Ann Oncol 2010. [Epub ahead of print]
    • (2010) Ann. Oncol.
    • Blay, J.Y.1
  • 117
    • 78650050500 scopus 로고    scopus 로고
    • Activity of eribulin mesylate E7389 in patients with soft tissue sarcoma STS: Phase II studies of the European organisation for research and treatment of cancer soft tissue and bone sarcoma group eortc 62052
    • abstract 1003
    • Schoffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052). J Clin Oncol 2010;28(15S):abstract 10031
    • (2010) J. Clin. Oncol. , vol.28
    • Schoffski, P.1    Ray-Coquard, I.L.2    Cioffi, A.3
  • 118
    • 75449117196 scopus 로고    scopus 로고
    • A SARC global collaborative phase II trial of R1507 a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor IGF1R in patients with recurrent or refractory sarcomas
    • abstract 1050
    • Patel S, Pappo A, Crowley J, et al. A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. J Clin Oncol 2010;27(15S):abstract 10503
    • (2010) J. Clin. Oncol. , vol.27
    • Patel, S.1    Pappo, A.2    Crowley, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.